All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

dopamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics	947	51-61-6

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: dopamine oxytyramine dopamin dophamine hydroxytyramin dopamine hydrochloride dopamine HCl

One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Molecular weight: 153.18 Formula: C8H11NO2 CLOGP: 0.17 LIPINSKI: 0 HAC: 3 HDO: 3 TPSA: 66.48 ALOGS: -1.31 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.50	g	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	470 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution)	0.74 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	65.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.87 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.42 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 25, 1974	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	92.68	25.26	52	3429	50285	50551358
Cardiac arrest	64.14	25.26	50	3431	83601	50518042
Renal ischaemia	62.24	25.26	13	3468	569	50601074
PCO2 increased	53.51	25.26	13	3468	1130	50600513
PO2 increased	52.37	25.26	12	3469	810	50600833
Blood bicarbonate decreased	50.95	25.26	15	3466	2710	50598933
Hypotension	50.56	25.26	71	3410	235398	50366245
Cardiogenic shock	48.64	25.26	23	3458	15576	50586067
Diabetes insipidus	48.57	25.26	14	3467	2350	50599293
Oxygen saturation abnormal	46.72	25.26	14	3467	2688	50598955
Blood pH decreased	43.66	25.26	13	3468	2442	50599201
Status epilepticus	42.51	25.26	20	3461	13386	50588257
Ventricular tachycardia	42.30	25.26	21	3460	15800	50585843
Foetal death	41.54	25.26	17	3464	8163	50593480
Enzyme induction	37.50	25.26	6	3475	56	50601587
Renal impairment	37.04	25.26	35	3446	75626	50526017
Shock	34.37	25.26	20	3461	20630	50581013
Renal injury	34.10	25.26	15	3466	8596	50593047
Pulmonary oedema	32.66	25.26	27	3454	48911	50552732
Newborn persistent pulmonary hypertension	32.21	25.26	6	3475	144	50601499
Bradycardia	31.90	25.26	30	3451	64396	50537247
Cardiopulmonary failure	31.70	25.26	11	3470	3362	50598281
Cardiac assistance device user	31.42	25.26	5	3476	45	50601598
Electroencephalogram abnormal	31.30	25.26	11	3470	3488	50598155
Seizure	30.50	25.26	39	3442	117835	50483808
Blood magnesium decreased	30.38	25.26	15	3466	11145	50590498
Renal failure	30.34	25.26	37	3444	106596	50495047
Disseminated intravascular coagulation	29.59	25.26	17	3464	17118	50584525
Clonus	29.40	25.26	11	3470	4164	50597479
Metabolic acidosis	29.25	25.26	23	3458	38802	50562841
Drug ineffective	28.42	25.26	121	3360	819212	49782431
Left ventricular dysfunction	28.24	25.26	14	3467	10492	50591151
Blood pressure decreased	27.61	25.26	26	3455	55883	50545760
Electrocardiogram QRS complex prolonged	26.77	25.26	11	3470	5333	50596310
Systolic anterior motion of mitral valve	26.42	25.26	4	3477	25	50601618

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	54.39	20.11	52	3630	63064	29507781
Drug ineffective	48.21	20.11	125	3557	363045	29207800
Disseminated intravascular coagulation	47.29	20.11	30	3652	19950	29550895
Ventricular fibrillation	40.55	20.11	25	3657	15808	29555037
Hypotension	39.08	20.11	79	3603	194275	29376570
Torsade de pointes	38.27	20.11	18	3664	6643	29564202
Blood urea increased	38.05	20.11	30	3652	28082	29542763
Shock	29.30	20.11	23	3659	21381	29549464
Metabolic acidosis	28.61	20.11	29	3653	37633	29533212
Acute kidney injury	27.80	20.11	84	3598	265183	29305662
Cardiogenic shock	27.08	20.11	21	3661	19169	29551676
Cardiac arrest	25.03	20.11	41	3641	85550	29485295
Neutrophil count increased	24.97	20.11	18	3664	14724	29556121
Lymphocyte count decreased	24.85	20.11	20	3662	19251	29551594
Acidosis	24.02	20.11	15	3667	9690	29561155
Dry gangrene	22.94	20.11	6	3676	385	29570460
Respiratory failure	22.51	20.11	42	3640	97089	29473756
Hypernatraemia	22.37	20.11	13	3669	7373	29563472
Renal failure	22.33	20.11	47	3635	118552	29452293
Incision site pain	20.91	20.11	8	3674	1775	29569070

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	101.13	21.64	83	6447	101330	64390872
Hypotension	74.69	21.64	136	6394	380838	64111364
Cardiac arrest	73.39	21.64	84	6446	153980	64338222
Disseminated intravascular coagulation	71.12	21.64	43	6487	32305	64459897
Cardiogenic shock	65.91	21.64	41	6489	32386	64459816
Blood urea increased	58.93	21.64	43	6487	44110	64448092
Ventricular fibrillation	58.40	21.64	34	6496	23826	64468376
Drug ineffective	57.95	21.64	201	6329	840046	63652156
Shock	55.05	21.64	39	6491	38201	64454001
Ventricular tachycardia	49.45	21.64	35	6495	34230	64457972
Renal ischaemia	49.20	21.64	13	6517	1070	64491132
PCO2 increased	48.04	21.64	14	6516	1653	64490549
Metabolic acidosis	44.86	21.64	45	6485	70913	64421289
Diabetes insipidus	41.34	21.64	16	6514	4505	64487697
Respiratory failure	41.34	21.64	65	6465	161118	64331084
Septic shock	41.14	21.64	52	6478	105385	64386817
PO2 increased	40.66	21.64	12	6518	1480	64490722
Foetal death	40.46	21.64	17	6513	5913	64486289
Blood pH decreased	38.21	21.64	15	6515	4387	64487815
Oxygen saturation abnormal	37.57	21.64	14	6516	3557	64488645
Blood bicarbonate decreased	36.86	21.64	15	6515	4814	64487388
Acute kidney injury	36.60	21.64	114	6416	449126	64043076
Renal impairment	33.98	21.64	54	6476	134963	64357239
Renal failure	33.11	21.64	63	6467	181625	64310577
Torsade de pointes	32.88	21.64	21	6509	17342	64474860
Bradycardia	32.14	21.64	49	6481	118170	64374032
Platelet count decreased	31.60	21.64	59	6471	167652	64324550
Enzyme induction	31.48	21.64	6	6524	109	64492093
Blood pressure decreased	31.24	21.64	41	6489	86158	64406044
Pulmonary oedema	30.99	21.64	39	6491	78635	64413567
Neutrophil count increased	30.18	21.64	23	6507	25151	64467051
Acidosis	29.97	21.64	20	6510	17775	64474427
Fatigue	29.40	21.64	20	6510	748710	63743492
Hypernatraemia	28.84	21.64	17	6513	12172	64480030
Status epilepticus	28.66	21.64	21	6509	21642	64470560
Cardiac assistance device user	28.02	21.64	5	6525	62	64492140
Sepsis	27.18	21.64	67	6463	230274	64261928
Arthralgia	26.83	21.64	6	6524	442254	64049948
Incision site pain	26.44	21.64	10	6520	2644	64489558
Left ventricular dysfunction	26.04	21.64	18	6512	16936	64475266
Seizure	25.74	21.64	54	6476	166838	64325364
Systolic dysfunction	24.62	21.64	10	6520	3192	64489010
Blood magnesium decreased	24.31	21.64	16	6514	13889	64478313
Cardiac failure	22.99	21.64	45	6485	132328	64359874
Electroencephalogram abnormal	22.96	21.64	11	6519	5192	64487010
Hepatic function abnormal	22.38	21.64	30	6500	64283	64427919
N-terminal prohormone brain natriuretic peptide	22.17	21.64	4	6526	53	64492149
Systolic anterior motion of mitral valve	22.17	21.64	4	6526	53	64492149
Urine output decreased	21.85	21.64	16	6514	16476	64475726

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01CA04	CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents
FDA CS	M0003647	Catecholamines
FDA EPC	N0000175570	Catecholamine
MeSH PA	D002316	Cardiotonic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D020011	Protective Agents
MeSH PA	D013566	Sympathomimetics
CHEBI has role	CHEBI:35522	beta-adrenergic agonists
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:38147	cardiotonic drugs
CHEBI has role	CHEBI:48560	dopaminergic agents
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:76971	Escherichia coli metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Low cardiac output syndrome	indication	44088000
Low blood pressure	indication	45007003
Decompensated cardiac failure	indication	195111005
Sinus bradycardia	off-label use	49710005
Acute nephropathy	off-label use	58574008
Tachyarrhythmia	contraindication	6285003
Hypovolemia	contraindication	28560003
Ventricular arrhythmia	contraindication	44103008
Acidosis	contraindication	51387008
Pheochromocytoma	contraindication	302835009
Hypoxia	contraindication	389086002
Occlusive Vascular Disease	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.96	acidic
pKa2	12.98	acidic
pKa3	10.61	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	AGONIST	Ki	5		WOMBAT-PK	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Kd	4.19		CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN	AGONIST	Ki	9		WOMBAT-PK
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	AGONIST	Ki	9		WOMBAT-PK
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		IC50	8.18		WOMBAT-PK
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.08		PDSP
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	AGONIST	Ki	9		WOMBAT-PK
D(1B) dopamine receptor	GPCR	P21918	DRD5_HUMAN	AGONIST	Ki	9		WOMBAT-PK
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.19		CHEMBL
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN	AGONIST	Ki	9		WOMBAT-PK
Trace amine-associated receptor 1	GPCR	Q96RJ0	TAAR1_HUMAN		Ki	6.38		WOMBAT-PK
Melatonin receptor type 1A	GPCR	P48039	MTR1A_HUMAN		Ki	5.15		CHEMBL
Melatonin receptor type 1B	GPCR	P49286	MTR1B_HUMAN		Ki	5.04		CHEMBL
Lysine-specific demethylase 4E	Enzyme	B2RXH2	KDM4E_HUMAN		IC50	5.52		CHEMBL
Dopamine beta-hydroxylase	Enzyme	P09172	DOPO_HUMAN		Km	3		WOMBAT-PK
FAD-linked sulfhydryl oxidase ALR	Enzyme	P55789	ALR_HUMAN		AC50	5.85		CHEMBL
Alpha-synuclein	Transporter	P37840	SYUA_HUMAN		IC50	6.28		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	8.35		CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		IC50	6.70		CHEMBL
D(1A) dopamine receptor	GPCR		DRD1_BOVIN		Ki	8.15		CHEMBL
Beta-1 adrenergic receptor	GPCR		ADRB1_RAT		Ki	5		CHEMBL
D(1A) dopamine receptor	GPCR		DRD1_RAT		Ki	6.82		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_BOVIN		Ki	8.74		CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_CANFA		Ki	4.30		CHEMBL
D(3) dopamine receptor	GPCR		DRD3_RAT		Ki	7.96		CHEMBL
D(4) dopamine receptor	GPCR		DRD4_RAT		EC50	8.62		CHEMBL
Opioid receptor	GPCR		OPRD_RAT OPRM_RAT OPRK_RAT SGMR1_RAT		IC50	5.52		CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2B_RAT ADA2C_RAT ADA2A_RAT		Ki	7.24		CHEMBL
Dopamine receptor	GPCR		DRD2_BOVIN DRD1_BOVIN		IC50	8.43		CHEMBL
Dopamine receptor	GPCR		DRD1_RAT DRD3_RAT DRD5_RAT DRD4_RAT DRD2_RAT		IC50	5.27		CHEMBL
Adrenergic receptor alpha-1	GPCR		ADA1B_RAT ADA1D_RAT ADA1A_RAT		Ki	4.85		CHEMBL
Adenylate cyclase	Enzyme		D4A3N4_RAT ADCY3_RAT ADCY2_RAT ADCY4_RAT ADCY8_RAT ADCY6_RAT ADCY5_RAT Q8CFM9_RAT		EC50	5.46		CHEMBL
Adenosine A2b receptor	GPCR		AA2BR_RAT		Ki	6.01		CHEMBL
M18 aspartyl aminopeptidase	Enzyme		Q8I2J3_PLAF7		IC50	5.70		CHEMBL

External reference:

ID	Source
4019733	VUID
N0000147825	NUI
D00633	KEGG_DRUG
62-31-7	SECONDARY_CAS_RN
4018656	VANDF
4019733	VANDF
C0013030	UMLSCUI
CHEBI:18243	CHEBI
LDP	PDB_CHEM_ID
CHEMBL59	ChEMBL_ID
DB00988	DRUGBANK_ID
CHEMBL1557	ChEMBL_ID
D004298	MESH_DESCRIPTOR_UI
681	PUBCHEM_CID
2417	INN_ID
940	IUPHAR_LIGAND_ID
VTD58H1Z2X	UNII
3628	RXNORM
3090	MMSL
4632	MMSL
6641	MMSL
d00216	MMSL
001787	NDDF
004721	NDDF
16257000	SNOMEDCT_US
412383006	SNOMEDCT_US
59187003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9252	INJECTION	40 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9252	INJECTION	40 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9253	INJECTION	80 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9253	INJECTION	80 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9254	INJECTION	40 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9254	INJECTION	40 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9255	INJECTION	80 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9255	INJECTION	80 mg	INTRAVENOUS	ANDA	16 sections
MYOCARD-DX	HUMAN PRESCRIPTION DRUG LABEL	2	0264-1840	INJECTION	80 mg	INTRAVENOUS	EXPORT ONLY	20 sections
MYOCARD-DX	HUMAN PRESCRIPTION DRUG LABEL	2	0264-1880	INJECTION	800 mg	INTRAVENOUS	EXPORT ONLY	20 sections
Dopamine Hydrochloride and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1005	INJECTION, SOLUTION	80 mg	INTRAVENOUS	NDA	22 sections
Dopamine Hydrochloride and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1007	INJECTION, SOLUTION	160 mg	INTRAVENOUS	NDA	22 sections
Dopamine Hydrochloride and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1009	INJECTION, SOLUTION	320 mg	INTRAVENOUS	NDA	22 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9981	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	11 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9982	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	11 sections
DOPamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5820	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	17 sections
Dopamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7809	INJECTION, SOLUTION	1.60 mg	INTRAVENOUS	NDA	25 sections
Dopamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7810	INJECTION, SOLUTION	3.20 mg	INTRAVENOUS	NDA	25 sections
DOPamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9104	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	17 sections
DOPAMINE HCI	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1220	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	12 sections
DOPAMINE HCI	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1291	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	12 sections
DOPAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1316	INJECTION, SOLUTION	1.60 mg	INTRAVENOUS	NDA	13 sections
DOPAMINE HCI IN 5% DEXTROSE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1458	INJECTION, SOLUTION	1.60 mg	INTRAVENOUS	NDA	13 sections
DOPAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1489	INJECTION	40 mg	INTRAVENOUS	ANDA	11 sections
DOPAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1490	INJECTION	40 mg	INTRAVENOUS	ANDA	11 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	52584-104	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	11 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	52584-820	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	11 sections
DOPamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	71872-7066	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	17 sections